Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation

The timing pattern in which dipeptidyl-peptidase IV inhibitors (DPP4i) confer the risk of bullous pemphigoid (BP) is unknown. To investigate the odds of BP following exposure to DPP4i and to perform a duration-response analysis evaluating the risk of BP in relation to the duration of exposure to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kridin, Khalaf, Avni, Orly, Damiani, Giovanni, Tzur Bitan, Dana, Onn, Erez, Weinstein, Orly, Cohen, Arnon D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813067/
https://www.ncbi.nlm.nih.gov/pubmed/35032198
http://dx.doi.org/10.1007/s00403-021-02317-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813067/
https://www.ncbi.nlm.nih.gov/pubmed/35032198
http://dx.doi.org/10.1007/s00403-021-02317-9

Ejemplares similares